Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity. Issue 12 (23rd December 2015)

• Record Type: Journal Article
• Authors: Poynard, Thierry; Deckmyn, Olivier; Munteanu, Mona; Ngo, Yen; Drane, Fabienne; Castille, Jean Marie; Housset, Chantal; Ratziu, Vlad
• Is Part Of: BMJ open. Volume 5:Issue 12(2015)
• Publication Date: 2015-12-23
• Subjects: Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2015-010017
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Background: Effective antiviral treatment (direct-acting antiviral agents (DAAs)), the requirement for a fibrosis score to support DDA reimbursement and a screening strategy, such as the USA baby boomer campaign, should lead to an increased awareness of liver disease severity. Objective: To compare the awareness of liver disease severity between the USA and France, two countries with similar access to hepatitis C virus (HCV) and hepatitis B virus (HBV) treatments, similar rules for treatment reimbursement and similar availability of validated fibrosis tests, but with different policies, as France has no screening. Method: The global database of the FibroTest–ActiTest, including 1 085 657 subjects between 2002 and 2014, was retrospectively analysed. Awareness was defined as the test prescription rate and was compared between the USA and France, according to year of birth, gender and dates of DAA availability and screening campaign (2013–2014). Results: In the USA 252 688 subjects were investigated for HCV, with a dramatic increase (138%) in the test rate in 2013–2014 (119 271) compared with 2011–2012 (50 031). In France 470 762 subjects were investigated (subjects with HCV and other disease) and the rates were stable. In USA 82.4% of subjects and in France 84.6% were classified as either the highest or lowest priority. The most striking difference was the higher test rate in women born between 1935 and 1944 in France 30 384/200 672 (15.1%) compared with the USA 8035/97 079 (8.3%) (OR=1.98 (95% CI 1.93 to 2.03) p<0.0001). This resulted in twice as many cases of cirrhosis being detected, 2.6% (5191/200 672 women) and 1.3% (1303/97 079), respectively, despite the same prevalence of cirrhosis in this age group (17.1% vs 16.2%) and without any clear explanation as to why they had not been included in the USA screening. Conclusions: This study highlighted in the USA the association between awareness of liver disease and both the HCV campaign and DAA availability. In comparison with France, there was a dramatically lower awareness of cirrhosis in the USA for women born between 1935 and 1944.